ArticlePloS one2012
In vivo fluorescence lifetime imaging monitors binding of specific probes to cancer biomarkers.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 36 citations in OpenAlex.
- Fluorescence lifetime of injected indocyanine green as a universal marker of solid tumours in patients.Nature biomedical engineering · 2023Article
- Phasor Analysis of Fluorescence Lifetime Enables Quantitative Multiplexed Molecular Imaging of Three Probes.Analytical chemistry · 2022Article
- Fluorescence lifetime imaging microscopy: fundamentals and advances in instrumentation, analysis, and applications.Journal of biomedical optics · 2020Review
- Using in vivo fluorescence lifetime imaging to detect HER2-positive tumors.EJNMMI research · 2018Article
- Cancer Immunotherapy Getting Brainy: Visualizing the Distinctive CNS Metastatic Niche to Illuminate Therapeutic Resistance.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2017Review
- Evaluation of breast tissue with confocal strip-mosaicking microscopy: a test approach emulating pathology-like examination.Journal of biomedical optics · 2017Article
- Molecular probes for fluorescence lifetime imaging.Bioconjugate chemistry · 2015Review
- Effect of Ca²⁺ on the steady-state and time-resolved emission properties of the genetically encoded fluorescent sensor CatchER.The journal of physical chemistry. B · 2015Article
- In vivo assessment of HER2 receptor density in HER2-positive tumors by near-infrared imaging, using repeated injections of the fluorescent probe.Technology in cancer research & treatment · 2014Article
- In vivo fluorescence lifetime imaging for monitoring the efficacy of the cancer treatment.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- Multiscale BerEp4 molecular imaging of microtumor phantoms: toward theranostics for basal cell carcinoma.Molecular imaging · 2014Article
- Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors.Cancer immunology, immunotherapy : CII · 2013Article
- Optical imaging of cell death in traumatic brain injury using a heat shock protein-90 alkylator.Cell death & disease · 2013Article
- Article
- In vivo validation of quantitative frequency domain fluorescence tomography.Journal of biomedical optics · 2012Article
- FLIM-FRET for Cancer Applications.Current molecular imagingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 2 countries.
Funding
Abstract
One of the most important factors in choosing a treatment strategy for cancer is characterization of biomarkers in cancer cells. Particularly, recent advances in Monoclonal Antibodies (MAB) as primary-specific drugs targeting tumor receptors show that their efficacy depends strongly on characterization of tumor biomarkers. Assessment of their status in individual patients would facilitate selection of an optimal treatment strategy, and the continuous monitoring of those biomarkers and their binding process to the therapy would provide a means for early evaluation of the efficacy of therapeutic intervention. In this study we have demonstrated for the first time in live animals that the fluorescence lifetime can be used to detect the binding of targeted optical probes to the extracellular receptors on tumor cells in vivo. The rationale was that fluorescence lifetime of a specific probe is sensitive to local environment and/or affinity to other molecules. We attached Near-InfraRed (NIR) fluorescent probes to Human Epidermal Growth Factor 2 (HER2/neu)-specific Affibody molecules and used our time-resolved optical system to compare the fluorescence lifetime of the optical probes that were bound and unbound to tumor cells in live mice. Our results show that the fluorescence lifetime changes in our model system delineate HER2 receptor bound from the unbound probe in vivo. Thus, this method is useful as a specific marker of the receptor binding process, which can open a new paradigm in the "image and treat" concept, especially for early evaluation of the efficacy of the therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.